RxDoctor Payments Data

Arnel Castrence, MD

Internal Medicine · Waldorf, MDNPI 1225092968

Payments from drug & device makers

$491in general payments, 2019–2025

Across 21 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$83
  • Amgen$67
  • Advanced Oxygen Therapy Inc.$50
  • Dynavax Technologies Corporation$39
  • AbbVie$36
  • Tactile Systems Technology Inc$31
  • plus $186 from 9 others

What the payments were for

  • Food & beverage$491100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$491 in reported general payments places this provider in the 60th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$131,012
Medicare patients
387
Services billed
2,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$83,146
OzempicSemaglutide46$61,403
MounjaroTirzepatide37$57,535
EliquisApixaban43$53,585
JanuviaSitagliptin Phosphate18$18,245
TradjentaLinagliptin14$12,520
Breo ElliptaFluticasone/Vilanterol12$6,942
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,126
Varenicline Tartrate12$3,673
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,840
Atorvastatin Calcium305$2,802
Rosuvastatin Calcium131$2,191
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,965
Valsartan41$1,718
Gabapentin71$1,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$61,40346 claims
Lilly USA, LLCMounjaro$23$57,53537 claims
AbbVieSynthroid$36$76816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Waldorf

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →